Tectonic Therapeutic, Inc. quarterly report, Q1 FY2023

Filing summary

Entity discrepancy: The request identifies Tectonic Therapeutic, Inc., but the supplied Form 10-Q is for AVROBIO, Inc. (Nasdaq: AVRO). This summary reflects the supplied filing, not Tectonic Therapeutic.

Business context and reporting period

Unaudited results cover the three months ended March 31, 2023, with balance-sheet comparisons to December 31, 2022. AVROBIO is a clinical-stage gene therapy company developing ex vivo lentiviral therapies for rare diseases. It reported no product revenue. Its programs include Gaucher disease, cystinosis, Hunter syndrome and Pompe disease; Fabry has been deprioritized.

Financial and operating metrics

Cash and cash equivalents were $72.3 million at March 31, 2023, down from $92.6 million at year-end 2022. Total assets were $83.0 million; total liabilities were $30.0 million. The company had $15.0 million principal outstanding under its term loan (carrying value, net of discount, $15.4 million), with principal payments scheduled to begin in 2024 and maturity in October 2026. Current liabilities were $14.3 million versus current assets of $77.3 million. Gross margin is not meaningful because the company had no product revenue.

Changes, outlook and material developments

• Net loss narrowed by $4.9 million year over year, largely as operating expenses declined by $4.2 million and net other income improved by $0.7 million. R&D expense fell $1.9 million; G&A fell $2.3 million. Management attributed the R&D decrease mainly to lower personnel costs, partly offset by higher clinical-trial consulting expenses.
• Operating cash use declined by $7.7 million year over year. Management said March 31 cash was expected to fund operations and capital needs into the first quarter of 2024, but warned that assumptions could prove wrong and cash could run out sooner.
• The financial statements state that cash may not be sufficient for at least the next 12 months after issuance and identify substantial doubt about the company’s ability to continue as a going concern. Additional funding is needed; availability and terms are uncertain.
• AVR-RD-02: five patients dosed and six enrolled in the Guard1 Gaucher type 1 trial as of March 20, 2023. A global Phase 2/3 Gaucher type 3 trial was planned for the second half of 2023, subject to regulatory alignment. AVR-RD-04’s collaborator-sponsored cystinosis trial had dosed six patients; a company-sponsored trial was planned for the second half of 2023, subject to regulatory clearance. The University of Manchester’s Hunter syndrome trial began in April 2023. The company no longer expected to start a Pompe clinical trial in 2023.
• In March 2023, SVB was closed and its deposits and loans were subsequently acquired by First Citizens Bank. The company reported that depositors had access to their funds, was pursuing alternative banking arrangements, and had a covenant waiver through May 19, 2023 while it sought account-control agreements for outside accounts.
• After the quarter, former CEO Geoff MacKay resigned effective May 1, 2023; CFO Erik Ostrowski became interim CEO while the company searched for a permanent CEO. On May 11, 2023, Nasdaq notified the company it had again fallen below the $1.00 minimum bid price; the stated compliance deadline was November 7, 2023.

Risks, contingencies and unusual items

Key risks include funding shortfalls and going-concern uncertainty; clinical, regulatory, enrollment and manufacturing uncertainty; potential gene-therapy and conditioning-related adverse effects; dependence on third-party and sole-source suppliers; loan covenants and limited access to contingent borrowing; and possible Nasdaq delisting. The filing reports no material pending or threatened litigation. It also discloses up to $80 million in potential development and regulatory milestones under the University of Manchester license, plus an expected aggregate trial-funding commitment of approximately £9.9 million under the related research agreement; these are not current-period expenses in their entirety.

Important facts for investors to verify

• Confirm the intended issuer: the supplied filing is AVROBIO, not Tectonic Therapeutic.
• Review the cash-runway estimate against the going-concern disclosure and the company’s subsequent financing or strategic actions.
• Check the status of the SVB-related covenant waiver, alternative banking arrangements and account-control agreements.
• Verify trial starts, enrollment, regulatory clearances and whether the planned 2023 milestones were achieved.
• Check subsequent Nasdaq bid-price compliance and any action affecting listing status.
• Assess debt terms, available borrowing (including the Fabry-related tranche no longer available), potential dilution and outstanding equity awards.